期刊文献+

醛固酮合成酶和盐皮质激素受体基因在充血性心力衰竭心肌的表达 被引量:4

Expression of aldosterone synthase and mineralocorticoid receptor gene in failing human heart
下载PDF
导出
摘要 目的 研究醛固酮合成酶 (Aldosterone synthase,CYP11B2 )及盐皮质激素受体 (Mineralocorticoid receptor,MR)基因在心功能不全心肌中的表达。方法 选取 2 5例行瓣膜置换术的慢性心力衰竭 (CHF)患者左心室乳头肌组织 10 0 mg,同时取 6例健康心肌组织作为对照 ,提取组织总 RNA,并逆转录为 c DNA,以特定的寡核苷酸为引物进行聚合酶链反应 ,β- actin作为内参照 ,分别观察 CYP11B2及 MR在不同心功能状态心肌中的表达。结果 在 6例正常心肌组织中 CYP11B2基因的表达为阴性 ,2 5例 CHF患者中有 10例表达阳性 ,分别为心功能 级~ 级 2例 , 级~ 级 8例 ;轻度心力衰竭患者 (心功能 ~ 级 )与重度心力衰竭患者 (心功能 ~ 级 )表达阳性率分别为 15 .4 %和 6 6 .7% ,差异有显著性 (P=0 .0 15 )。正常心肌、心功能 ~ 级和心功能 ~ 级心肌 MR/ β- actin分别为 1.2 8± 0 .13,0 .92± 0 .12 ,0 .80± 0 .2 1,与正常对照组相比 ,CHF时 MR基因表达明显下降 (P<0 .0 0 1) ,而心功能 ~ 级与心功能 ~ 级之间 ,无显著性差异 (P=0 .0 83)。慢性心力衰竭患者中 ,CYP11B2基因表达阳性与阴性组之间 MR/ β- actin表达分别为 0 .78± 0 .2 0和 0 .94± 0 .13,二者间具有显著性差异 (P=0 .0 18)。 Objective To investigate the expression level of aldosterone synthase(CYP11B2) gene and mineralocorticoid receptor (MR)gene in failing human heart. Metheods The 25 specimens came from patients with chronic congestive heart failure who had been hospitalized for operation. CYP11B2 gene and MR gene expression were detec ted by reverse transcription polymerase chain reaction(RT-PCR) methods. The function of left ventricle was assessed by echocardiography. Results CYP11B2 gene expressed in 10/25 biopsies in patients with congestive heart failure and none in 6 cases of heart tissue from normal adult. One specimen expressed CYP11B2 gene in the group of NYHA class Ⅰ, one in NYHA class Ⅱ, five in NYHA class Ⅲ and 3 expressed in NYHA class Ⅳ; CYP11B2 expressed 15.4% in the group of patients with mild heart failure(NYHA classⅠ~Ⅱ) and 66.7% in severe heart failure(NYHA class Ⅲ~Ⅳ). The expression of CYP11B2 in severe congestive heart failure was significantly hig her than that in mild heart failure(P=0.015). MR mRNA was detected in all specimens. The expression of MR gene was down-regulated in the patients with CHF. The value of MR/β-actin was 1.28±0.13, 0.92±0.12, 0.80 ±0.21 in normal adult heart , heart tissue from mild heart failure and from severe heart failure(F=16.86, P< 0.001 ), respectively. But the difference of MR/β-actin between the subgroups of CHF(NYHA classⅠ~Ⅱand NYHA class Ⅲ~Ⅳ) was not significant (P=0.08).Furthermore, the value of MR/β-actin in the myocardial tissue where CYP11B2 positively expressed was significantly lower than it in the cardial tissue where CYP11B2 negatively expressed(P=0.018).Conclusion CYP11B2 gene expression is activated in the severe congestive heart failure, while MR gene expression is down-regulated in CHF. The activation of CYP11B2 gene is associated with the severe left ventricular dysfunction in human CHF.
出处 《中国心血管杂志》 2004年第3期186-190,共5页 Chinese Journal of Cardiovascular Medicine
关键词 醛固酮合成酶 盐皮质激素受体 充血性心力衰竭 醛固酮 逆转录聚合酶链反应 Aldosterone synthase Mineralocorticoid receptor Congestive heart failure Aldosterone Reverse transcription polymerase chain reaction
  • 相关文献

参考文献10

  • 1Gomez-Sanchez CE, Zhou MY, Cozza EN, et al.Aldosterone biosynthesis in the rat brain[J]. Endocrinology, 1997,138 : 3369-3373.
  • 2Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in rat Physiological regulation[J]. J Biol chem, 1998,273:4883-4891.
  • 3Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans[J]. Circulation, 2001,103 : 72-77.
  • 4Colucci WS. Molecular and cellular mechanisms of myocardial failure [J]. Am J Cardiol, 1997, 80(11A) :15L-25L.
  • 5Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart[J]. J Clin Endocrinol Metab, 2000, 85 : 2519-2525.
  • 6Mamoru S, Motoyuki N, Hidenori S, et al. Aldosterone synthase (CYP11B2) expression in failing human heart[J]. Clinical Science,2002, 102:381-386.
  • 7Yoshimura M, Nakamura S, Ito T, et al. Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real-time polymerase chain reaction[J]. J Clin Endocrinol Metab, 2002, 87: 3936-3940.
  • 8Volpe M, Gigante B, Enea I, et al. Role of tissue renin in the regulation of aldosterone biosynthesis in the adrenal cortex of nephrectomized rats[J]. Circ Res, 1997, 81:857-864.
  • 9Falkenstein E, Tillmannn HC, Christ M, et al. Mutiple actions of steroid hormones-A focus on rapid,nongenomic effects[J]. Pharmacol Rev, 2000, 52513-555.
  • 10Ikeda U, Hyman R, Smith TW, et al. Aldosterone mediated regulation of Na^+K^+-ATPase gene expression in adult and neonatal rat cardiocytes[J]. J Biol Chem,1991, 266:12058-12066.

同被引文献31

  • 1刘进平,韩涛,浦晓东.血管紧张素Ⅱ受体研究进展[J].福建医药杂志,2006,28(4):97-99. 被引量:2
  • 2王蕾,姚东云,马红梅,张伯礼.中药利尿药理实验动物筛选方法探讨[J].中国比较医学杂志,2006,16(11):694-696. 被引量:22
  • 3高纯,林春艳,顾国浩.血管紧张素受体研究新进展[J].广东医学,2007,28(4):657-659. 被引量:3
  • 4Nishiyama A, Abe Y. Aldosterone and renal injury. J Nippon Yakurigaku Zasshi,2004 ;124(2) : 101 - 109.
  • 5Luther JM, Luo P, Wang Z, et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury [J]. Kidney Int, 2012, 82(6) : 643-651.
  • 6Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure ( EMPHASIS-HF ) [ J ] Circ Heart Fail, 2014, 7(1) : 51-58.
  • 7Mehdi UF, Adama-Huet B, Raskin P, et al. Addition ?I angiotensin receptor blockade or mineralocorticoi antagonism to maximal angiotensin-converting enzyme inhi-I bition in diabetic nephropathy [ J ]. J Am Soc Nephrol~ 2009, 20(12): 2 641-650. |.
  • 8Iqbal J, Andrew R, Cruden NL, et al. Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist [ J ]. J Clin Endocrinol Metab, 2014, 99(3): 915-922.
  • 9van den Berg TN, Rongen GA, Frohlich GM, et al. The cardioprotective effects of mineralocorticoid receptor antagonists[J]. Pharmacol Ther, 2014, 142(1) : 72-87.
  • 10Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury[ J]. J Cardiovasc Pharmaeol, 2014, 64( 1): 69-78.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部